SEC Filing Summary
2026-09-04SEC Filing 4 (0001193125-26-383625)
Christopher Horan, Chief Tech Operations Officer at Artiva Biotherapeutics, Inc., reported a sale of 10,366 shares of common stock on September 3, 2026. The sale was executed under a "sell-to-cover" policy to satisfy tax withholding obligations related to the vesting of restricted stock units. The weighted average sale price was $11.1555, with prices ranging from $11.0301 to $11.1556. Following this transaction, Horan owns 283,084 shares of common stock.